Colfax Reports Fourth Quarter, Full Year 2009 Results
RICHMOND, Va., Feb. 18 /PRNewswire-FirstCall/ -- Colfax Corporation (NYSE: CFX), a global leader in fluid-handling solutions for critical applications, today announced financial results for the fourth quarter and full year ended December 31, 2009. On a year-over-year basis, highlights for the quarter and the year include:
Fourth quarter of 2009 (all comparisons versus the fourth quarter of 2008)
- Net income of $5.1 million (12 cents per share – basic and diluted) including restructuring and other related charges of $7.4 million; adjusted net income (as defined below) of $11.2 million (26 cents per share), a decrease of 35.7% including positive currency effects of 2 cents per share
- Net sales of $131.0 million, a decrease of 17.8%; organic sales decline (as defined below) of 23.5%
- Operating income of $9.0 million; adjusted operating income (as defined below) of $18.3 million, a decrease of 36.2% including positive currency effects of $1.0 million
- EBITDA (as defined below) of $12.8 million; adjusted EBITDA (as defined below) of $22.1 million, a decrease of 31.1% including positive currency effects of $1.2 million
- Fourth quarter orders of $101.6 million, a decrease of 22.4%; organic order decline (as defined below) of 28.3%
- Backlog of $290.9 million at period end
Full year 2009 (all comparisons versus 2008)
- Net income of $21.7 million (50 cents per share – basic and diluted) including restructuring and other related charges of $18.2 million; adjusted net income (as defined below) of $40.1 million (93 cents per share), a decrease of 25.3% including negative currency effects of 9 cents per share
- Net sales of $525.0 million, a decrease of 13.2%; organic sales decline (as defined below) of 8.1%
- Operating income of $38.5 million; adjusted operating income (as defined below) of $66.2 million, a decrease of 27.1% including negative currency effects of $5.4 million
- EBITDA (as defined below) of $52.9 million; adjusted EBITDA (as defined below) of $80.6 million, a decrease of 23.7% including negative currency effects of $5.9 million
- Orders for the year of $462.4 million, a decrease of 32.2%; organic order decline (as defined below) of 29.0%.
Adjusted net income, adjusted net income per share, adjusted operating income, EBITDA, adjusted EBITDA, organic sales growth (decline) and organic order growth (decline) are not financial measures calculated in accordance with generally accepted accounting principles in the U.S. ("GAAP"). See below for a description of the measures' usefulness and a reconciliation of these measures to their most directly comparable preliminary GAAP financial measures.
"Our fourth quarter results came in as expected," said Clay Kiefaber, President and CEO of Colfax Corporation. "Looking at the year, Colfax faced a challenging environment. Sales were down 8% organically, driven by a 25% decline in our general industrial end market. A sharp rebound in our navy business helped to mitigate the impact of the weakness in general industrial. Organic orders decreased 29% in 2009 with declines in all markets except global navy which had a significant order increase of 72%. We made substantial progress on our restructuring efforts during the year as evidenced by our gross profit margin. We're continuing to implement our cost reduction plans which will help us leverage our cost structure as markets improve."
He added, "We are beginning to see some signs of economic recovery including sequential order improvement in the general industrial end market. However, we expect our businesses to continue to be under pressure in 2010 as most of them are later-cycle businesses and lag the broader economy. Our strong financial condition provides us with the flexibility to continue to weather current conditions. We remain focused on our growth initiatives in key end markets, cost reductions, and acquisition opportunities which will better position us when our markets fully recover. Based on our current backlog and order rates, we are expecting organic sales to decline in the range of 5% to 9% and adjusted net income per share to be $.67 to $.77 for 2010."
Non-GAAP Financial Measures and Other Adjustments
Colfax has provided in this press release financial information that has not been prepared in accordance with GAAP. These non-GAAP financial measures are adjusted net income, adjusted net income per share, adjusted operating income, EBITDA, adjusted EBITDA, organic sales growth (decline) and organic order growth (decline). Adjusted net income, adjusted net income per share, adjusted operating income and adjusted EBITDA exclude asbestos liability and defense costs (income) and asbestos coverage litigation expenses, certain legacy legal charges, certain due diligence costs, restructuring and other related charges as well as one time initial public offering-related costs to the extent they impact the periods presented. Adjusted net income also reflects interest expense as if the initial public offering (IPO) had occurred at the beginning of 2007 and presents income taxes at an effective tax rate of 32% in 2009 and 34% in 2008. Adjusted net income per share in 2008 assumes the 44,006,026 shares outstanding at the closing of the IPO to be outstanding since January 1, 2007. Projected adjusted net income per share excludes actual and estimated restructuring and other related charges, asbestos coverage litigation expenses and asbestos liability and defense costs. Organic sales growth (decline) and organic order growth (decline) exclude the impact of acquisitions and foreign exchange rate fluctuations. These non-GAAP financial measures assist Colfax in comparing its operating performance on a consistent basis because, among other things, they remove the impact of changes in our capital structure and asset base, non-recurring items such as IPO-related costs, legacy asbestos issues (except in the case of EBITDA) and items outside the control of its operating management team.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of non-GAAP financial measures presented above to preliminary GAAP results has been provided in the financial tables included in this press release.
At December 31, 2009, the Company standardized its definition of an order among its businesses, as well as the methodology for calculating the currency impact on backlog. Orders and backlog are presented in accordance with the revised methodology for all periods presented. As a result, orders for the quarter and year ended December 31, 2008 increased by $4.7 million, or 3.7%, and $12.9 million, or 1.9%, respectively. Backlog for the year ended December 31, 2008 increased by $11.6 million, or 3.4%. Applying the revised methodology, orders for the quarter and year ended December 31, 2009 decreased by $3.8 million, or 3.6%, and increased $7.7 million, or 1.7%, respectively. Backlog for 2009 increased by $21.7 million, or 8.1%.
Conference Call and Webcast
Colfax will host a conference call to provide details about its results and outlook on Thursday, February 18 at 8:00 a.m. ET. The call will be open to the public through 877-303-7908 or 678-373-0875 and webcast via Colfax's website at http://www.colfaxcorp.com under the "Investor Relations" section. Access to a supplemental slide presentation can also be found at the Colfax website under the same heading. Both the audio of this call and the slide presentation will be archived on the website later today and will be available until the next quarterly call.
About Colfax Corporation
Colfax Corporation is a global leader in critical fluid-handling products and technologies. Through its global operating subsidiaries, Colfax manufactures positive displacement industrial pumps and valves used in oil & gas, power generation, commercial marine, global naval and general industrial markets. Colfax's operating subsidiaries supply products under the well-known brands Allweiler, Fairmount Automation, Houttuin, Imo, LSC, Portland Valve, Tushaco, Warren and Zenith. Colfax is traded on the NYSE under the ticker "CFX." Additional information about Colfax is available at www.colfaxcorp.com.
CAUTIONARY NOTE CONCERNING FORWARD LOOKING STATEMENTS:
This press release may contain forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Colfax's plans, objectives, expectations and intentions and other statements that are not historical or current facts. Forward-looking statements are based on Colfax's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Colfax's results to differ materially from current expectations include, but are not limited to factors detailed in Colfax's reports filed with the U.S. Securities and Exchange Commission as well as its Annual Report on Form 10-K under the caption "Risk Factors". In addition, these statements are based on a number of assumptions that are subject to change. This press release speaks only as of this date. Colfax disclaims any duty to update the information herein.
The term "Colfax" in reference to the activities described in this press release may mean one or more of Colfax's global operating subsidiaries and/or their internal business divisions and does not necessarily indicate activities engaged in by Colfax Corporation.
Colfax Corporation
Condensed Consolidated Statements of Operations
Dollars in thousands, except per share data
(Unaudited)
Three Months Ended Year Ended
December 31, December 31, December 31, December 31,
2009 2008 2009 2008
---- ---- ---- ----
Net sales $130,971 $159,311 $525,024 $604,854
Cost of sales 83,960 101,557 339,237 387,667
------ ------- ------- -------
Gross profit 47,011 57,754 185,787 217,187
Initial public
offering
related costs - - - 57,017
Selling,
general and
administrative
expenses 27,426 27,718 113,674 125,234
Research and
development
expenses 1,320 1,426 5,930 5,856
Restructuring
and other
related
charges 7,420 - 18,175 -
Asbestos
liability and
defense
(income) costs (1,017) 1,978 (2,193) (4,771)
Asbestos
coverage
litigation
expenses 2,904 4,905 11,742 17,162
----- ----- ------ ------
Operating
income 8,958 21,727 38,459 16,689
Interest
expense 1,746 2,138 7,212 11,822
----- ----- ----- ------
Income before
income taxes 7,212 19,589 31,247 4,867
Provision for
income taxes 2,092 9,210 9,525 5,438
----- ----- ----- -----
Net income
(loss) $5,120 $10,379 $21,722 $(571)
====== ======= ======= =====
Net income
(loss) per
share-basic
and diluted $0.12 $0.24 $0.50 $(0.11)
===== ===== ===== ======
Colfax Corporation
Condensed Consolidated Balance Sheets
Dollars in thousands
(Preliminary and unaudited)
December 31,
2009 2008
---- ----
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $49,963 $28,762
Trade receivables, less allowance for doubtful
accounts 88,493 101,064
Inventories, net 71,150 80,327
Asbestos insurance asset 30,606 26,473
Asbestos insurance receivable 28,991 36,371
Other current assets 20,358 21,860
------ ------
Total current assets 289,561 294,857
Deferred income taxes, net 52,023 53,428
Property, plant and equipment, net 90,434 92,090
Goodwill and intangible assets, net 179,206 179,046
Long-term asbestos insurance asset 358,843 277,542
Long-term asbestos insurance receivable 16,876 -
Deferred loan costs, pension and other assets 16,188 16,113
------ ------
Total assets $1,003,131 $913,076
========== ========
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Current portion of long-term debt and capital
leases $8,969 $5,420
Accounts payable 36,579 52,138
Accrued asbestos liability 34,866 28,574
Other accrued liabilities 63,785 68,154
------ ------
Total current liabilities 144,199 154,286
Long-term debt, less current portion 82,516 91,701
Long-term asbestos liability 408,903 328,684
Pension and accrued post-retirement benefits 126,953 130,188
Other liabilities 41,728 41,286
------ ------
Total liabilities 804,299 746,145
Shareholder's equity 198,832 166,931
------- -------
Total liabilities and shareholders' equity $1,003,131 $913,076
========== ========
Colfax Corporation
Condensed Consolidated Statement of Cash Flows
Dollars in thousands
(Preliminary and unaudited)
Year ended
December 31,
2009 2008
---- ----
Cash flows from operating activities:
Net income (loss) $21,722 $(571)
Adjustments to reconcile net income (loss) to
cash provided by (used in) operating activities:
Depreciation, amortization and fixed asset
impairment charges 15,074 14,788
Noncash stock-based compensation 2,593 11,330
Other adjustments for non-cash items 613 5,608
Deferred income taxes 3,593 (13,357)
Changes in working capital 6,144 (29,148)
Changes in other operating assets and
liabilities (11,453) (21,631)
------- -------
Net cash provided by (used in) operating
activities 38,286 (32,981)
Cash flows from investing activities:
Purchases of fixed assets (11,006) (18,645)
Acquisitions, net of cash received (1,260) (439)
Proceeds from sale of fixed assets 219 23
--- --
Net cash used in investing activities (12,047) (19,061)
Cash flows from financing activities:
Borrowings under term credit facility - 100,000
Payments under term credit facility (5,000) (210,278)
Proceeds from borrowings on revolving credit
facilities - 28,185
Repayments of borrowings on revolving credit
facilities - (28,158)
Proceeds from the issuance of common stock, net
of offering costs - 193,020
Repurchases of common stock - (5,731)
Dividends paid to preferred shareholders - (38,546)
Other (417) (3,656)
---- ------
Net cash (used in) provided by financing
activities (5,417) 34,836
Effect of exchange rates on cash 379 (2,125)
--- ------
Increase (decrease) in cash and cash equivalents 21,201 (19,331)
Cash and cash equivalents, beginning of year 28,762 48,093
------ ------
Cash and cash equivalents, end of year $49,963 $28,762
======= =======
Colfax Corporation
Reconciliation of GAAP to non-GAAP Financial Measures
Dollars in thousands, except per share data
(Unaudited)
Three Months Ended Year Ended
December 31, December 31, December 31, December 31,
2009 2008 2009 2008
---- ---- ---- ----
EBITDA
Net income
(loss) $5,120 $10,379 $21,722 $(571)
Interest
expense 1,746 2,138 7,212 11,822
Provision for
income taxes 2,092 9,210 9,525 5,438
Depreciation
and
amortization 3,834 3,443 14,426 14,788
----- ----- ------ ------
EBITDA $12,792 $25,170 $52,885 $31,477
======= ======= ======= =======
EBITDA margin 9.8% 15.8% 10.1% 5.2%
Adjusted EBITDA
Net income
(loss) $5,120 $10,379 $21,722 $(571)
Interest
expense 1,746 2,138 7,212 11,822
Provision for
income taxes 2,092 9,210 9,525 5,438
Depreciation
and
amortization 3,834 3,443 14,426 14,788
Restructuring
and other
related
charges 7,420 - 18,175 -
IPO-related
costs - - - 57,017
Legacy legal
adjustment - - - 4,131
Due diligence
costs - - - 582
Asbestos
liability and
defense
(income)
costs (1,017) 1,978 (2,193) (4,771)
Asbestos
coverage
litigation
expenses 2,904 4,905 11,742 17,162
----- ----- ------ ------
Adjusted
EBITDA $22,099 $32,053 $80,609 $105,598
======= ======= ======= ========
Adjusted
EBITDA margin 16.9% 20.1% 15.4% 17.5%
Adjusted Net Income
and Adjusted
Earnings per Share
Net income
(loss) $5,120 $10,379 $21,722 $(571)
Restructuring
and other
related
charges 7,420 - 18,175 -
IPO-related
costs - - - 57,017
Legacy legal
adjustment - - - 4,131
Due diligence
costs - - - 582
Asbestos
liability and
defense
(income)
costs (1,017) 1,978 (2,193) (4,771)
Asbestos
coverage
litigation
expenses 2,904 4,905 11,742 17,162
Interest
adjustment to
effect IPO at
beginning of
period - - - 2,302
Tax
adjustment to
effective
rate of 32%
and 34%,
respectively (3,194) 210 (9,346) (22,201)
------ --- ------ -------
Adjusted net
income $11,233 $17,472 $40,100 $53,651
======= ======= ======= =======
Adjusted net
income margin 8.6% 11.0% 7.6% 8.9%
Weighted
average
shares
outstanding -
diluted 43,449,493 - 43,325,704 -
Shares
outstanding
at closing of
IPO - 44,006,026 - 44,006,026
Adjusted net
income per
share $0.26 $0.40 $0.93 $1.22
===== ===== ===== =====
Net income
(loss) per
share-basic
and diluted
in accordance
with GAAP $0.12 $0.24 $0.50 $(0.11)
===== ===== ===== ======
Adjusted
Operating
Income
Operating
income $8,958 $21,727 $38,459 $16,689
Restructuring
and other
related
charges 7,420 - 18,175 -
IPO-related
costs - - - 57,017
Legacy legal
adjustment - - - 4,131
Due diligence
costs - - - 582
Asbestos
liability and
defense
(income)
costs (1,017) 1,978 (2,193) (4,771)
Asbestos
coverage
litigation
expenses 2,904 4,905 11,742 17,162
----- ----- ------ ------
Adjusted
operating
income $18,265 $28,610 $66,183 $90,810
======= ======= ======= =======
Adjusted
operating
income margin 13.9% 18.0% 12.6% 15.0%
Colfax Corporation
Change in Sales and Orders
Dollars in millions
(Unaudited)
Sales Orders
$ % $ %
--------------- ---------------
Three Months Ended
December 31, 2008 $159.3 $131.0
Components of Change:
Existing
Businesses (37.5) (23.5)% (37.1) (28.3)%
Acquisitions 0.5 0.3% 1.0 0.8%
Foreign
Currency
Translation 8.7 5.4% 6.7 5.1%
----- -----
Total (28.3) (17.8)% (29.4) (22.4)%
----- -----
Three Months Ended
December 31, 2009 $131.0 $101.6
====== ======
Sales Orders Backlog at
$ % $ % Period End
-------------- --------------- ---------------
Year ended
December 31, 2008 $604.9 $682.1 $349.0
Components of Change:
Existing Businesses (48.8) (8.1)% (198.0) (29.0)% (66.8) (19.1)%
Acquisitions 1.0 0.2% 1.4 0.2% 0.7 0.2%
Foreign Currency
Translation (32.1) (5.3)% (23.1) (3.4)% 8.0 2.3%
----- ------ -----
Total (79.9) (13.2)% (219.7) (32.2)% (58.1) (16.6)%
------ ------ ------
Year ended
December 31, 2009 $525.0 $462.4 $290.9
====== ====== ======
Colfax Corporation
Reconciliation of Projected 2010 Net Income Per Share
to Adjusted Net Income Per Share
Amounts in Dollars
(Unaudited)
EPS Range
---------
Projected net income per share - fully diluted $0.41 $0.51
Estimated restructuring and other related charges(1) 0.06 0.06
Asbestos coverage litigation 0.14 0.14
Asbestos liability and defense costs 0.06 0.06
---- ----
Projected adjusted net income per share - fully diluted $0.67 $0.77
===== =====
(1) Represents estimated costs related to restructuring actions
implemented through February 15, 2010, including $.03 per share of
termination benefits for the Company's former CEO. Assumes
continuation of the German furlough program throughout 2010.
SOURCE Colfax Corporation
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article